Atara Biotherapeutics (ATRA) investor relations material

Opening remarks and agenda

• Meeting called to order at 9:01 A.M. Pacific Time on June 9th, 2026, with introductions of board members, officers, and advisors present virtually.

• The meeting was hosted on a virtual platform, with procedures for voting and question submission explained.

• The agenda included four proposals: election of directors, advisory vote on executive compensation, amendment to the equity incentive plan, and ratification of the auditor.

Board and executive committee updates

• Board members and key officers were introduced, including the Chair, Chief Accounting Officer, SVP Regulatory Affairs, and Head of Legal.

Shareholder proposals

• Election of two directors to serve until the 2029 annual meeting.

• Advisory approval of executive compensation as described in the proxy statement.

• Approval of an amendment to the 2024 Equity Incentive Plan to increase reserved shares by 400,000.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.